Skip to Content

Gencaro Approval Status

  • FDA approved: No
  • Brand name: Gencaro
  • Generic name: bucindolol
  • Company: ARCA biopharma, Inc.
  • Treatment for: Heart Failure

Gencaro (bucindolol) is an investigational and pharmacologically unique beta-blocker and mild vasodilator in development for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population (heart failure patients with reduced left ventricular ejection fraction, HFREF).

Development Status and FDA Approval Process for Gencaro

Aug 18, 2016ARCA Biopharma Announces 100th Patient Randomized Into The GENETIC-AF Phase 2b/3 Clinical Trial
Apr 13, 2015ARCA Biopharma Receives FDA Fast Track Designation for Gencaro
Jun  1, 2009ARCA biopharma Receives Complete Response Letter From FDA on the Gencaro NDA
Sep 23, 2008FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.